R
Rezolute
Specializing in the development of drug therapies for patients with metabolic and orphan diseases
About Rezolute
A late-stage biopharmaceutical company that specializes in developing therapies for rare diseases. The company's primary focus is on conditions with significant unmet medical needs, particularly congenital hyperinsulinism (HI), a rare pediatric genetic disorder characterized by excessive insulin secretion, leading to persistent hypoglycemia.
The company's lead product candidate, RZ358, is a human monoclonal antibody that is in late-stage clinical development for the treatment of congenital HI. RZ358 is designed to bind to and inhibit the activity of insulin, thereby reducing the frequency and severity of hypoglycemic events. Rezolute is also developing RZ402, an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME).
The company's business model is centered on the development and commercialization of its product candidates. Rezolute's target market includes pediatric and adult patients with rare diseases, as well as the physicians and healthcare providers who treat them. The company's revenue model will be based on the sale of its approved products.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2010
- Headquarters
- Louisville, United States
- Listing
- IPO 2012
- Employees
- 73
- Open positions
- 7
- Dealroom signal
- 74.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Personal Health, Diabetes, Risk Management, Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Apr 2025 | $90M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jun 2024 | $6.7M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$80M | — |
| 2025 | $0 | — | −$80M | — |
| 2024 | $0 | — | −$67M | — |
| 2023 | $0 | — | −$52M | — |
| 2022 | $0 | — | −$42M | — |
| 2021 | $0 | — | −$22M | — |
| 2020 | $0 | — | −$20M | — |
Growth signals
Latest recorded traffic for Rezolute is 4.4K monthly website visits, down 18.5% over the last three months. Rezolute's team declined 14.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later6 investors entered at this stage
PH Pharma
Genexine- HAHANDOK
CAM Capital
SLR Capital Partners
Armentum Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rezolute on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rezolute’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.